Executive record

Andrew Einhorn

Director at Pelthos Therapeutics Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:andrew-einhornVersion: public-0As of: 2026-09-29

Not yet claimed8 published Claims3 sources
  • Director

Key Claims

Biography

Consultant and fractional CFO at Danforth Advisors for biotech companies. Previously CFO of RVL Pharmaceuticals (2017-2022) and Edge Therapeutics (2013-2017). Co-founder and CFO of three specialty pharmaceutical companies. Investment banker for 20 years (1983-2003).

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedPTHS 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec proxy · Source published: Aug 18, 2026 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at Pelthos Therapeutics Inc. · Claim reviewed: Sep 12, 2026

  2. PTHS 10-K executive officers

    sec filing · Source published: Mar 19, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Pelthos Therapeutics Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Andrew Einhorn is also linked to Danforth Advisors as Consultant/Fractional CFO. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Pelthos Therapeutics Inc. · Claim reviewed: Sep 12, 2026